In chronic myelogenous leukemia, a translocation occurs between chromosomes 9
and 22. This rearrangement of genomic material creates a fusion gene call
Bcr-Abl that produces a protein (tyrosine kinase) thought to promote the
development of leukemia. The drug Gleevec blocks the activation of the Bcr-Abl
protein.